Additionally, in comparison to Prox-1 and LYVE-1, it is more sensitive in recognizing lymphangiogenesis in breast cancer and displays the strongest immunoreactivity in both intratumoral and peritumoral LECs (39–41). The gene discussed is PROX1; the disease is breast carcinoma.